TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6402
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution 1.0%
Study: 6402
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution 1.5%
Study: 6402
Drug: Timolol ophthalmic
Normalized name: timolol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol ophthalmic solution (all concentrations)
Study: 25962601
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of adalimumab (ADA) after 12 months of treatment
Study: 17855815
Drug: Early hemodynamic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early hemodynamic optimization strategies (early goal-directed therapy)
Study: 14713799
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release ciprofloxacin 1,000 mg once daily
Study: 14713799
Drug: Conventional ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional ciprofloxacin 500 mg twice daily
Study: 8632216
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin A supplements
Study: 1575179
Drug: Duteplase (rt-PA)
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duteplase (rt-PA) maintenance infusion at doses of 0.012, 0.024, 0.036, 0.048 MIU/kg/hour for 9 to 21 hours
Study: 1575179
Drug: Total dose
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of rt-PA administered
Study: 26824595
Drug: Acetazolamide administration
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide administration and prone positioning for 10 days
Study: 9151795
Drug: cM‐T412 (chimeric
Approvals — FDA: no, EMA: no, PMDA: no
Description: cM‐T412 (chimeric CD4 monoclonal antibody)
Study: 2655367
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of intravenous regional analgesia technique (removal of excess local anaesthetic solution)
Study: 2655367
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of excess local anaesthetic agent after 15 min
Study: 1108754
Drug: Loperamide 2
Normalized name: loperamide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 2 mg capsules, optimal daily dose ranged from two to seven capsules.
Study: 1108754
Drug: Loperamide 2
Normalized name: loperamide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 2 mg capsules (in double-blind placebo-controlled trial for ten days or until relapse).
Study: 1108754
Drug: Loperamide 2
Normalized name: loperamide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 2 mg capsules.
Study: 28722611
Drug: Ferroquine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferroquine + Artesunate (200 mg/day)
Study: 28722611
Drug: Amodiaquine (612
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (612 mg/day) + Artesunate (200 mg/day)
Study: 16924799
Drug: SCENAR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCENAR therapy
Study: 15180356
Drug: Mizolastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (10 mg)
Study: 14696020
Drug: Fexofenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (120 mg)
Study: 12903420
Drug: Alanyl‐glutamine [0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanyl‐glutamine [0.5 g/(kg.d)]
Study: 12903420
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (isocaloric parenteral nutrition without glutamine)
Study: 9350072
Drug: Metformin up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin up to 2000 mg day-1
Study: 31698478
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.035 mg/kg)
Study: 29856175
Drug: Blueberry juice
Normalized name: lowbush blueberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry juice (500 mL/day for 14 days preoperatively)
Study: 17199952
Drug: Amiodarone 100
Normalized name: amiodarone 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 100 mg daily (Group B)
Study: 14618939
Drug: DEAE-Dextran at
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEAE-Dextran at 2.5 g/day
Study: 7627695
Drug: Probucol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (0.5 g BID) added to diet and cholestyramine (8 g BID)
Study: 7627695
Drug: Probucol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (0.5 g BID)
Study: 2035782
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% amethocaine hydrochloride
Study: 30089792
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of APL daily containing 970 mg of dihydromyricetin
Study: 30089792
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 g of APL daily without dihydromyricetin)
Study: 28610718
Drug: Echinacea purpurea-derived
Normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea-derived alkylamides (Ec. extract) cream
Study: 12586132
Drug: Clivarin (4200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clivarin (4200 U once daily subcutaneous)
Study: 1469
Drug: Community alternative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community alternative treatment
Study: 7022244
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithymocyte globulin (ATG) administration
Study: 10549062
Drug: Placebo, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one similar capsule b.i.d. for 21 days
Study: 7796625
Drug: Cold crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold crystalloid cardioplegia (St. Thomas Hospital solution) with hypothermic CPB
Study: 30785826
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of epirubicin (E) 90 mg/m2 and cyclophosphamide (C) 600 mg/m2 followed by four cycles of docetaxel (T) 100 mg/m2
Study: 30785826
Drug: Six cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of docetaxel (T) 75 mg/m2 and cyclophosphamide (C) 600 mg/m2
Study: 15318308
Drug: ml/kg RBW
Approvals — FDA: no, EMA: no, PMDA: no
Description: ml/kg RBW method
Study: 15318308
Drug: ml/kg OBW
Approvals — FDA: no, EMA: no, PMDA: no
Description: ml/kg OBW method
Study: 15755229
Drug: Diet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet treatment
Study: 9221965
Drug: Clozapine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (150 mg/day for 31 days)
Study: 2880663
Drug: Visacor (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visacor (200 mg once daily)
Study: 19338146
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SFI)
Study: 21346105
Drug: Multi-micronutrient supplementation
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-micronutrient supplementation (daily biscuit)
Study: 19234585
Drug: Alpha-linolenic acid
Normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-linolenic acid (ALA) supplementation in flax oil (14 g/day)
Study: 24490806
Drug: Allegra® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allegra® tablets (phenylalanine-containing ODT)
Study: 7962890
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral treatment 1
Study: 7962890
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral treatment 2
Study: 23553618
Drug: High hardaliye
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hardaliye (HH) - 500 mL per day
Study: 23553618
Drug: Low hardaliye
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hardaliye (LH) - 250 mL per day
Study: 18779777
Drug: Adjunctive risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjunctive risperidone therapy
Study: 3080511
Drug: Astemizole (load),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (load), 30 mg once daily for 1 week and then 10 mg once daily for 1 week
Study: 3080511
Drug: Hydroxyzine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine, 50 mg once daily for 2 weeks
Study: 3080511
Drug: Terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 60 mg twice daily for 2 weeks
Study: 3080511
Drug: Astemizole (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (no load), 10 mg once daily for 2 weeks
Study: 24843499
Drug: Liraglutide 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.9 mg/day
Study: 24573588
Drug: Subatmospheric pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subatmospheric pressure therapy (SPT)
Study: 9025711
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 3 IU/m2 per day for 14 days
Study: 9025711
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 6 IU/m2 per day for 14 days
Study: 1603479
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin (6-mU/minute dosage increments)
Study: 31025209
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) and fractional ablative CO2 laser (FACL) treatment (three sessions at 1-month intervals)
Study: 31025209
Drug: Standard moisturizers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard moisturizers and silicone gels (control treatment)
Study: 22612620
Drug: Lansoprazole (LPZ)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LPZ) intravenous infusion at doses of 15 mg, 30 mg, and 60 mg
Study: 17999638
Drug: Vitamins C+E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamins C+E (1 g/day vitamin C plus 400 IU/day vitamin E)
Study: 10091618
Drug: Apomorphine (subcutaneously,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (subcutaneously, previously determined dose)
Study: 2026847
Drug: Pirenzepine (M1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (M1 antagonist)
Study: 2026847
Drug: 4-DAMP (M3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-DAMP (M3 antagonist)
Study: 2026847
Drug: AFDX-116 (M2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFDX-116 (M2 antagonist)
Study: 2026847
Drug: Antihistamines (pretreatment)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines (pretreatment)
Study: 30092143
Drug: H56:IC31 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H56:IC31 vaccine (two or three vaccinations at different concentrations)
Study: 30092143
Drug: H56:IC31 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H56:IC31 vaccine (various doses)
Study: 27481884
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride saline solution
Study: 25301251
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing intervention with a set of weighing scales
Study: 7557571
Drug: Fine bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine bran (15 g)
Study: 2162633
Drug: ANH group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANH group (7.5 ml/kg body weight within 30 min during substitution with 6% HES 200/0.5)
Study: 31267973
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic therapy
Study: 27458066
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-infection, reducing sputum, and support therapy)
Study: 25467927
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (lomustine, cyclophosphamide, etoposide)
Study: 25467927
Drug: Intravenous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous therapy (cyclophosphamide, doxorubicin, vincristine - CAV)
Study: 11586091
Drug: Pulsed paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulsed paclitaxel at 15 mg/m2
Study: 11586091
Drug: Pulsed paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulsed paclitaxel at 20 mg/m2
Study: 11586091
Drug: Pulsed paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulsed paclitaxel at 25 mg/m2
Study: 11586091
Drug: Pulsed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pulsed low-dose paclitaxel and radiation
Study: 10211011
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg kg‐1 ketoprofen i.v.
Study: 10211011
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg kg‐1 ketoprofen i.v.
Study: 10211011
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg kg‐1 ketoprofen i.v.
Study: 3411660
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin therapy
Study: 11340683
Drug: Once-daily tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tobramycin (Mono)
Study: 11340683
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with tobramycin/ceftazidime (Conv)
Study: 9448231
Drug: Nebulized flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized flunisolide nasal spray (250 microg, 1 ml, administered three times daily)
Study: 7960012
Drug: Ouabain standard
Normalized name: ouabain
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ouabain standard or bolus intravenous injections of ouabain
Study: 3109265
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (inhalation of air)
Study: 23214246
Drug: Zoledronic acid,
Normalized name: Zoledronic Acid, Anhydrous
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid, administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride
Study: 16081477
Drug: RhEPO (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhEPO (150 IU kg(‐1) weekly subcutaneous injection; n = 8)
Study: 16081477
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 ml sterile saline weekly subcutaneous injection; n = 7)
Study: 26822516
Drug: DHA-enriched meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched meals (1720 mg per day for 12 months)
Study: 23112272
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (doses > 50 U)
Study: 23112272
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (doses ≤ 50 U)
Study: 19761837
Drug: 7.5 microg
Normalized name: Levonorgestrel 37.5 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 microg H5N1 influenza vaccine without adjuvant
Study: 7989932
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or autologous transplantation (Control)
Study: 2659151
Drug: Atenolol 5
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 5 mg intravenously followed by 50 mg orally for six days
Study: 30622224
Drug: Rapid sequential
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid sequential injection of fentanyl followed by slow injection of hyperbaric bupivacaine
Study: 23883922
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² every 21 days or 35 mg/m² on days 1, 8, and 15 every 28 days
Study: 9014909
Drug: Killed whole‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole‐cell cholera vaccine (two doses per person)
Study: 8200247
Drug: Placebo (intramuscularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscularly monthly for three months)
Study: 18764913
Drug: Intranasal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxygen therapy
Study: 15231966
Drug: Atomoxetine (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.3 mg/kg once daily)
Study: 10195359
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg given once daily for 2 weeks
Study: 8995922
Drug: Evidence-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatment approaches
Study: 307358
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (propranolol therapy)
Study: 29734923
Drug: Tutor-administered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tutor-administered group (TAG)
Study: 31058772
Drug: Enhanced Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Protein Diet (EPD) with protein‐energy ratio 4 g/100 calories
Study: 25476156
Drug: 33% reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33% reduced dose radiography
Study: 15271701
Drug: Ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.1 mg/kg IV every 6 h)
Study: 9228472
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B 0.6 mg/kg/day (cumulative dose 8 mg/kg)
Study: 7962885
Drug: Cue Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue Exposure (CE) treatment with 400 min exposure to the sight and smell of preferred drinks over 10 days
Study: 20626325
Drug: N-acetylcysteine (NAC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC; 600 mg/day) with cisplatin
Study: 8871794
Drug: Individual behavioural-cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual behavioural-cognitive therapy
Study: 6655704
Drug: Marital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marital therapy
Study: 1627968
Drug: Buspirone (20-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (20-100 mg/day for 4 weeks)
Study: 12108557
Drug: Case managers'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case managers' verbal reminders about consequences of nonadherence to treatment
Study: 8578808
Drug: RRV‐S1 (serotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV‐S1 (serotype 1 monovalent rotavirus vaccine)
Study: 8578808
Drug: RRV vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV vaccines
Study: 17293228
Drug: Granulocyte-macrophage colony
Normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony stimulating factor (GM-CSF) 250 microg/m2, subcutaneous injection, 3 times a week
Study: 16573802
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily plus Aspirin 325 mg once daily (E40 b.d. + A325)
Study: 16573802
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily plus Rofecoxib 25 mg once daily (E40 b.d. + R25)
Study: 16573802
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily (E40 b.d.)
Study: 16573802
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg once daily (R25)
Study: 16573802
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Esomeprazole 40 mg b.d. and Rofecoxib 25 mg once daily)
Study: 12796713
Drug: 6.72% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.72% sodium lactate infusion at a rate of 50 micro mol. kg‐1. min‐1 for 20 minutes, then reduced to 30 micro mol. kg‐1. min‐1
Study: 12796713
Drug: 1.4% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4% sodium bicarbonate infusion
Study: 10352333
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg aspirin daily for 7 days
Study: 1742818
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg.kg‐1 and midazolam 0.2 mg.kg‐1 (Group I)
Study: 1742818
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg.kg‐1 and midazolam 0.4 mg.kg‐1 (Group II)
Study: 1742818
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of midazolam (0.4 mg.kg‐1)
Study: 26237453
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment plus SRP
Study: 20299535
Drug: Wake up
Normalized name: Wake Ups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wake up and breathe protocol (interrupts and reduces sedative exposure)